Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Invested Capital: 2009-2025

Historic Invested Capital for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $390.5 million.

  • Cytokinetics' Invested Capital fell 28.63% to $390.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $390.5 million, marking a year-over-year decrease of 28.63%. This contributed to the annual value of $425.8 million for FY2024, which is 143.56% up from last year.
  • Per Cytokinetics' latest filing, its Invested Capital stood at $390.5 million for Q3 2025, which was up 102.97% from $192.4 million recorded in Q2 2025.
  • Over the past 5 years, Cytokinetics' Invested Capital peaked at $669.7 million during Q2 2024, and registered a low of $101.2 million during Q3 2023.
  • In the last 3 years, Cytokinetics' Invested Capital had a median value of $294.7 million in 2025 and averaged $316.3 million.
  • In the last 5 years, Cytokinetics' Invested Capital soared by 550.32% in 2021 and then plummeted by 80.69% in 2023.
  • Cytokinetics' Invested Capital (Quarterly) stood at $243.9 million in 2021, then surged by 85.86% to $453.2 million in 2022, then plummeted by 61.43% to $174.8 million in 2023, then skyrocketed by 143.56% to $425.8 million in 2024, then fell by 28.63% to $390.5 million in 2025.
  • Its Invested Capital was $390.5 million in Q3 2025, compared to $192.4 million in Q2 2025 and $294.7 million in Q1 2025.